Vistagen Therapeutics, Inc. (VTGN)
| Previous Close | 4.8300 |
| Open | 4.8500 |
| Bid | 4.7000 x 100 |
| Ask | 4.7400 x 100 |
| Day's Range | 4.6500 - 4.8600 |
| 52 Week Range | 1.6200 - 24.7100 |
| Volume | |
| Avg. Volume | 265,041 |
| Market Cap | 127.505M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings Date | Jun 26, 2024 - Jul 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine c
Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
SOUTH SAN FRANCISCO, Calif., April 01, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).
Insider Monkey30 Countries with the Lowest Depression Rates
In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]
